Ninepoint Partners’s AbbVie ABBV Stock Holding History

Ninepoint Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$182K	Sell	797 -1,485	-65%	-$338K	0.02%	140
2025 Q3	$528K	Buy	+2,282	New	+$465K	0.07%	89
2025 Q2	–	Sell	-4,983	Closed	-$1.04M	–	88
2025 Q1	$1.04M	Buy	+4,983	New	+$969K	0.17%	60
2022 Q4	–	Sell	-2,933	Closed	-$394K	–	83
2022 Q3	$394K	Buy	+2,933	New	+$421K	0.05%	55

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Ninepoint Partners's ABBV Position: Q4 2025 in Review

Ninepoint Partners reduced its AbbVie (ABBV) stake by 65% in Q4 2025, selling an estimated $338K and leaving 797 shares worth $182K. The position accounts for 0.02% of the portfolio, ranked #140.

Ninepoint Partners first reported a position in ABBV in Q3 2022 and has held it in 4 quarters since. The position peaked at $1.04M in Q1 2025. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Ninepoint Partners held 797 shares of AbbVie worth $182K as of Q4 2025.
Ninepoint Partners sold 1,485 AbbVie shares in Q4 2025, an estimated $338K.
AbbVie made up 0.02% of Ninepoint Partners's portfolio in Q4 2025, its #140 holding.
Ninepoint Partners first reported a position in AbbVie in Q3 2022 and has held it in 4 quarters since.
Ninepoint Partners's AbbVie position peaked at $1.04M in Q1 2025.
4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Ninepoint Partners's 13F filing for Q4 2025, filed 17 Feb 2026.